Growth hormone secretion in Alzheimer's disease: 24-hour profile of basal levels and response to stimulation and suppression studies.

The 24-h growth hormone secretory pattern and GH response to growth hormone releasing hormone, the alpha 2-adrenoceptor agonist clonidine and the somatostatin-analogue SMS 201-995 were evaluated in 9 patients with Alzheimer's disease and 9 age- and body body-matched control subjects. The secretory profile did not differentiate between patients and controls. Both secreted the largest amount of GH during the early nighthours between 22.00-02.00, whereas the majority of daytime GH levels were below the assay's detection limit (0.4 ng/ml). No difference was found in GH response to GHRH between patients and controls. All subjects showed significantly enhanced GH secretion after GHRH. Dividing the patients into two groups according to age-of-onset (less than 60 years greater than), there was a trend toward larger GH responses to GHRH for the early-onset group. No other parameter differentiated the groups. GH levels after clonidine were blunted in all subjects but one AD patient, probably due to an age-dependent attenuation frequently observed in subjects over 45 years of age. Finally, the administration of the somatostatin-analogue did not render conclusive results, since spontaneous decline of GH concentration was already beginning 2 hours before the drug was given and continued steadily throughout the observation period. In conclusion, patients with only mild to moderate degree of Alzheimer's disease have no prominent changes in GH regulation.

Haloperidol- and SCH23390-induced dopaminergic supersensitivities are not additive in the rat.

The effect of chronic D-1 and/or D-2 dopamine receptor blockade on apomorphine-induced behaviors was studied in rats treated for 21 days with the selective D-1 antagonist SCH23390, the predominantly D-2 antagonist haloperidol, and the combination of the two drugs at the same daily doses (0.1 and 1 mg/kg respectively). Apomorphine (0.3 mg/kg) 4 days following the last injection of the drugs increased (49-70%) stereotypic behavior in all animals as compared to saline-treated controls. Although the SCH23390-induced increase was lower than haloperidol-induced supersensitivity, stereotypies after combined administration of both drugs did not differ significantly from either, suggesting that the effects of the two drugs are not additive. Underlying receptor changes and modified D-1/D-2 receptor interactions may account for the participation of both receptor subtypes to the development of neuroleptic-induced dopaminergic supersensitivity.

Leucemia monoblástica aguda: santuario cutáneo / Acute monoblastic leukemia: cutaneous santuaries

Presentamos una leucemia monoblástica aguda con múltiples infiltrados dérmicos específicos iniciales rebeldes a la quimioterapia, hematológicamente eficaz. Insistimos en la necesidad de diagnosticar (impronta) y evaluar la magnitud de los mismos con fines diagnósticos (biopsia), así como en la detección de posibles santuarios cutáneos, para lo cual la inmunomarcación de muramidasa resultó de gran valor

Leucemia monoblástica aguda: santuario cutáneo / Acute monoblastic leukemia: cutaneous santuaries

Presentamos una leucemia monoblástica aguda con múltiples infiltrados dérmicos específicos iniciales rebeldes a la quimioterapia, hematológicamente eficaz. Insistimos en la necesidad de diagnosticar (impronta) y evaluar la magnitud de los mismos con fines diagnósticos (biopsia), así como en la detección de posibles santuarios cutáneos, para lo cual la inmunomarcación de muramidasa resultó de gran valor (AU)